Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASRT NASDAQ:CASI NASDAQ:ENTX NASDAQ:QNCX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASRTAssertio$0.89-0.9%$0.82$0.51▼$1.16$85.28M0.28319,823 shs292,503 shsCASICASI Pharmaceuticals$1.86+1.6%$1.95$1.09▼$7.50$22.88M0.69471,999 shs40,652 shsENTXEntera Bio$1.89+2.7%$1.91$1.50▼$2.79$86.30M1.6896,184 shs37,728 shsQNCXQuince Therapeutics$1.78-8.7%$1.64$0.69▼$2.45$95.60M1.07242,062 shs1.62 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASRTAssertio-1.69%+0.54%+12.07%+29.86%-21.57%CASICASI Pharmaceuticals-1.08%+39.69%-21.79%+30.25%-66.91%ENTXEntera Bio-3.16%-5.64%-10.68%+3.37%-1.60%QNCXQuince Therapeutics+18.18%+21.12%+21.12%+21.12%+147.31%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASRTAssertio$0.89-0.9%$0.82$0.51▼$1.16$85.28M0.28319,823 shs292,503 shsCASICASI Pharmaceuticals$1.86+1.6%$1.95$1.09▼$7.50$22.88M0.69471,999 shs40,652 shsENTXEntera Bio$1.89+2.7%$1.91$1.50▼$2.79$86.30M1.6896,184 shs37,728 shsQNCXQuince Therapeutics$1.78-8.7%$1.64$0.69▼$2.45$95.60M1.07242,062 shs1.62 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASRTAssertio-1.69%+0.54%+12.07%+29.86%-21.57%CASICASI Pharmaceuticals-1.08%+39.69%-21.79%+30.25%-66.91%ENTXEntera Bio-3.16%-5.64%-10.68%+3.37%-1.60%QNCXQuince Therapeutics+18.18%+21.12%+21.12%+21.12%+147.31%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASRTAssertio 2.00Hold$2.38168.03% UpsideCASICASI Pharmaceuticals 2.00Hold$4.00115.05% UpsideENTXEntera Bio 2.50Moderate Buy$10.00429.10% UpsideQNCXQuince Therapeutics 3.00Buy$8.14357.46% UpsideCurrent Analyst Ratings BreakdownLatest CASI, QNCX, ASRT, and ENTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025ASRTAssertioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025CASICASI PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ENTXEntera BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025QNCXQuince TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/26/2025QNCXQuince TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.009/3/2025CASICASI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.008/26/2025QNCXQuince TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/25/2025ASRTAssertioZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell8/15/2025QNCXQuince TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.008/12/2025ASRTAssertioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$3.50 ➝ $3.008/12/2025QNCXQuince TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$9.00 ➝ $8.00(Data available from 10/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASRTAssertio$117.10M0.73$0.05 per share18.53$1.27 per share0.70CASICASI Pharmaceuticals$28.54M0.80N/AN/A$0.12 per share15.50ENTXEntera Bio$166K519.90N/AN/A$0.23 per share8.22QNCXQuince TherapeuticsN/AN/AN/AN/A$0.69 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASRTAssertio-$21.58M-$0.45N/A29.54N/A-36.97%-38.19%-15.45%11/10/2025 (Estimated)CASICASI Pharmaceuticals-$39.26M-$2.89N/A∞N/A-148.55%-972.55%-99.07%11/12/2025 (Estimated)ENTXEntera Bio-$9.54M-$0.26N/AN/AN/A-4,525.11%-77.75%-68.13%11/14/2025 (Estimated)QNCXQuince Therapeutics-$56.83M-$1.09N/AN/AN/AN/A-187.49%-42.47%11/12/2025 (Estimated)Latest CASI, QNCX, ASRT, and ENTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/29/2025Q2 2025CASICASI Pharmaceuticals-$0.47-$0.86-$0.39-$0.86$6.28 million$4.18 million8/11/2025Q2 2025ASRTAssertio-$0.10-$0.17-$0.07-$0.17$27.86 million$29.22 million8/11/2025Q2 2025QNCXQuince Therapeutics-$0.28-$0.34-$0.06-$0.34N/AN/A8/8/2025Q2 2025ENTXEntera Bio-$0.11-$0.06+$0.05-$0.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASRTAssertioN/AN/AN/AN/AN/ACASICASI PharmaceuticalsN/AN/AN/AN/AN/AENTXEntera BioN/AN/AN/AN/AN/AQNCXQuince TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASRTAssertio0.421.591.34CASICASI PharmaceuticalsN/A0.480.39ENTXEntera BioN/A10.4710.47QNCXQuince Therapeutics1.455.005.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASRTAssertio48.96%CASICASI Pharmaceuticals22.23%ENTXEntera Bio14.11%QNCXQuince Therapeutics30.75%Insider OwnershipCompanyInsider OwnershipASRTAssertio4.00%CASICASI Pharmaceuticals21.24%ENTXEntera Bio10.38%QNCXQuince Therapeutics16.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASRTAssertio2096.24 million92.39 millionOptionableCASICASI Pharmaceuticals18012.30 million9.69 millionOptionableENTXEntera Bio2045.66 million40.92 millionOptionableQNCXQuince Therapeutics6053.71 million44.69 millionOptionableCASI, QNCX, ASRT, and ENTX HeadlinesRecent News About These CompaniesQuince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Recommendation of "Buy" from BrokeragesOctober 4 at 4:21 AM | marketbeat.comQuince Therapeutics, Inc. (QNCX) Analyst/Investor Day TranscriptOctober 2, 2025 | seekingalpha.comQuince Therapeutics (NASDAQ:QNCX) Trading Up 1.2% - What's Next?October 1, 2025 | americanbankingnews.comQuince Therapeutics (NASDAQ:QNCX) Stock Price Up 1.2% - Time to Buy?October 1, 2025 | marketbeat.comQuince Therapeutics (NASDAQ:QNCX) Earns "Buy" Rating from D. Boral CapitalSeptember 27, 2025 | americanbankingnews.comQuince Therapeutics' (QNCX) "Buy" Rating Reaffirmed at D. Boral CapitalSeptember 26, 2025 | marketbeat.comQuince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling StudySeptember 25, 2025 | businesswire.comQuince Therapeutics, Inc. - Special CallSeptember 24, 2025 | seekingalpha.comQuince Therapeutics to Host Virtual Investor Day on October 2, 2025September 11, 2025 | businesswire.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Receives Average Rating of "Buy" from BrokeragesSeptember 11, 2025 | marketbeat.comQuince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | businesswire.comQuince Therapeutics Inc News (QNCX) - Investing.comAugust 22, 2025 | investing.comQuince Therapeutics price target lowered to $8 from $9 at Citizens JMPAugust 12, 2025 | msn.comQuince Therapeutics Reports Q2 2025 Financial ResultsAugust 12, 2025 | msn.comQuince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial ResultsAugust 11, 2025 | businesswire.comJMP Securities Initiates Coverage of Quince Therapeutics (QNCX) with Market Outperform RecommendationAugust 5, 2025 | msn.comQuince Therapeutics, Inc. (QNCX) - Yahoo FinanceJuly 17, 2025 | finance.yahoo.comQuince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-TelangiectasiaJuly 16, 2025 | businesswire.comQuince Therapeutics Appoints Leading Immunologist Dr. Hassan ...July 12, 2025 | finance.yahoo.comQuince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory BoardJuly 10, 2025 | businesswire.comQuince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research ConferenceJune 25, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCASI, QNCX, ASRT, and ENTX Company DescriptionsAssertio NASDAQ:ASRT$0.89 -0.01 (-0.89%) Closing price 04:00 PM EasternExtended Trading$0.91 +0.03 (+2.92%) As of 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.CASI Pharmaceuticals NASDAQ:CASI$1.86 +0.03 (+1.64%) Closing price 04:00 PM EasternExtended Trading$1.88 +0.01 (+0.81%) As of 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.Entera Bio NASDAQ:ENTX$1.89 +0.05 (+2.72%) Closing price 04:00 PM EasternExtended Trading$1.92 +0.04 (+1.85%) As of 05:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.Quince Therapeutics NASDAQ:QNCX$1.78 -0.17 (-8.72%) Closing price 04:00 PM EasternExtended Trading$1.79 +0.01 (+0.56%) As of 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Dividend Aristocrats to Buy Before Year’s End Joby's Stock Rallies as Public Flights Validate Global Game Plan SharkNinja Is Flashing a Buy Signal the Market Is Ignoring Why Semtech Stock Is Rallying After Its NVIDIA Setback Marvell Insiders Buy Shares—Should Investors Follow Suit? TrumpRx Brings Pfizer Into the Green—Is It a Buy? Behind D-Wave's Massive Week (And Why Rivals Also Popped) Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
